Eventide Asset Management LLC Trims Stake in Celcuity, Inc. $CELC

Eventide Asset Management LLC lowered its holdings in Celcuity, Inc. (NASDAQ:CELC) by 80.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 313,679 shares of the company’s stock after selling 1,275,120 shares during the quarter. Eventide Asset Management LLC owned 0.68% of Celcuity worth $31,287,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its position in Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after purchasing an additional 319 shares during the period. Meeder Asset Management Inc. purchased a new stake in Celcuity in the fourth quarter valued at $42,000. Ogorek Anthony Joseph NY ADV raised its position in Celcuity by 19.7% in the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock valued at $66,000 after purchasing an additional 109 shares during the period. US Bancorp DE raised its position in Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares during the period. Finally, NBC Securities Inc. purchased a new stake in Celcuity in the fourth quarter valued at $99,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Price Performance

CELC stock opened at $88.55 on Friday. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. The company has a market capitalization of $4.32 billion, a PE ratio of -22.71 and a beta of 0.10. Celcuity, Inc. has a 12-month low of $11.27 and a 12-month high of $151.02. The business’s fifty day moving average price is $119.81 and its 200 day moving average price is $111.22.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.10. On average, sell-side analysts anticipate that Celcuity, Inc. will post -3.69 EPS for the current year.

Insider Activity

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the sale, the director owned 6,760 shares in the company, valued at $949,509.60. This represents a 57.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director owned 65,000 shares in the company, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 37,000 shares of company stock worth $5,111,950. 13.33% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CELC. Wells Fargo & Company cut their price objective on Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, June 3rd. Weiss Ratings upgraded Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Guggenheim reiterated a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd. Macquarie Infrastructure set a $160.00 price objective on Celcuity in a report on Thursday, May 28th. Finally, Leerink Partners set a $155.00 price objective on Celcuity in a report on Tuesday, June 2nd. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $152.09.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.